Semaglutide tablets strength: how the dose ladder works for weight loss

Step 1: starting at 1.5 mg and why the lowest strength matters most

Every course of Wegovy tablets begins at 1.5 mg once daily. That is not a dose intended to produce significant weight loss, its job is to let your gut adjust to semaglutide before the concentration climbs. GLP-1 medicines slow gastric emptying, which is central to how they reduce appetite, but the same mechanism causes most of the nausea and digestive discomfort people experience early on. Starting low and holding there for at least a month keeps those effects manageable for the majority of people.

Timing matters with oral semaglutide in a way the injection doesn't require. The tablet is taken first thing in the morning, on a completely empty stomach, with no more than a small glass of plain water. You wait at least 30 minutes before eating, drinking coffee, or taking other oral medicines. That window exists because the absorption enhancer in the tablet (SNAC) needs an acidic, empty stomach to carry semaglutide across the gut wall; even a sip of coffee can reduce absorption meaningfully. It's one of those practical details that patients tell us they wish someone had flagged before they started.

The 1.5 mg starting dose is non-negotiable for anyone new to the tablet form. A prescriber cannot safely skip it, regardless of previous experience with the injection.

Step 2: moving through 4 mg and 9 mg (the intermediate strengths

After at least one month at 1.5 mg, the prescriber may increase to 4 mg) again for a minimum of one month, before the next step to 9 mg. These intermediate strengths are where most of the tolerability work happens. Weight loss typically becomes more noticeable through this phase as the dose climbs, but the body also needs time at each level before the prescriber considers whether to go further.

The 4 mg and 9 mg strengths are not shortcuts or stepping stones to skip. Some people stay longer at one level if they are still experiencing side effects that haven't fully settled. Others may find the prescriber recommends pausing an increase following a period of illness. These are clinical judgements, not deviations from the plan. You can read more about how the tablet dosing schedule is structured and what drives those decisions.

It's also worth being clear about what these strengths are not. The 3 mg, 7 mg, and 14 mg oral semaglutide tablets that sometimes appear in search results are Rybelsus, a product licensed solely for type 2 diabetes management. If you've come across a page discussing 7 mg oral semaglutide in a weight-loss context, it almost certainly needs clarification: that strength is not part of the Wegovy weight-management tablet schedule.

Step 3: reaching 25 mg, the maintenance dose and what the trial evidence shows

The 25 mg tablet is the licensed maintenance dose for weight management. A minimum of one month at 9 mg comes first, after which the prescriber decides whether to move up. Once at 25 mg, that dose is maintained for as long as treatment continues, subject to ongoing clinical review.

The clinical evidence comes from the OASIS 4 phase 3 trial, which studied 307 adults with obesity or overweight alongside at least one weight-related condition, over 64 weeks. Average weight loss was around 13.6% compared with approximately 2.4% in the placebo group. Among participants who stayed fully adherent to treatment throughout the trial, average weight loss was around 16.6%. Those figures come from semaglutide's clinical profile as summarised across UK regulatory materials following the June 2026 MHRA approval.

For those wondering how the tablet compares with the injection in terms of dose for weight loss, there is a dedicated page comparing the oral and injectable semaglutide dose approaches that sets out what the evidence currently shows. The tablet and injection are not interchangeable by dose number, 25 mg oral and 2.4 mg subcutaneous are both maintenance doses, but the route of administration means the numbers cannot be compared directly.

A note on the injection-to-tablet transition and cost context

Patients who are already stable on the 2.4 mg weekly injection form of Wegovy may be eligible to move directly to the 25 mg tablet, bypassing the earlier steps. This transition is subject to clinical assessment, it is not automatic, and a prescriber needs to confirm it is appropriate for your specific situation before any change is made.

One practical advantage of the tablet over the injection is storage. Wegovy tablets require no refrigeration; they can be kept at room temperature, which makes everyday life and travel considerably simpler. There are no needles, no sharps disposal, and no need to plan around a fridge. For some people that matters a great deal; for others the injection suits them better. The Wegovy tablet overview covers those practical differences in more detail.

Cost is a real consideration for anyone weighing up options. Private treatment pricing varies by provider and by which strength you are currently prescribed; our treatment page sets out what is included in a single transparent price at nume, with no subscription and no hidden prescription or delivery fees. If you are still at the research stage, the oral semaglutide dose and weight-loss outcomes page gives a fuller picture of what the evidence currently supports at each stage of treatment.

Wegovy tablets are available as a private prescription only in the UK at launch, a NICE appraisal would be required before any NHS coverage. That process takes time, so for now, regulated private routes like those covered here are the only practical option for most people.